Meeting
2023 ASCO Annual Meeting
Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
Authors
Manish Kohli
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Manish Kohli , Maura Dougherty , Zachary Cutshall , Rylee Beckstead , Rhea Kohli , Benjamin Haaland , Richard Nelson , Minkyoung Yoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5081)
DOI
10.1200/JCO.2023.41.16_suppl.5081
Abstract #
5081
Poster Bd #
175
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
First Author: Manish Kohli
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.
First Author: Sreevalsa Appukkuttan
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment and survival of de novo metastatic prostate cancer in US veterans.
First Author: Martin W. Schoen